» Articles » PMID: 15647387

Inhibition of Complex I of the Electron Transport Chain Causes O2-. -mediated Mitochondrial Outgrowth

Overview
Specialties Cell Biology
Physiology
Date 2005 Jan 14
PMID 15647387
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Recent evidence indicates that oxidative stress is central to the pathogenesis of a wide variety of degenerative diseases, aging, and cancer. Oxidative stress occurs when the delicate balance between production and detoxification of reactive oxygen species is disturbed. Mammalian cells respond to this condition in several ways, among which is a change in mitochondrial morphology. In the present study, we have used rotenone, an inhibitor of complex I of the respiratory chain, which is thought to increase mitochondrial O(2)(-)* production, and mitoquinone (MitoQ), a mitochondria-targeted antioxidant, to investigate the relationship between mitochondrial O(2)(-)* production and morphology in human skin fibroblasts. Video-rate confocal microscopy of cells pulse loaded with the mitochondria-specific cation rhodamine 123, followed by automated analysis of mitochondrial morphology, revealed that chronic rotenone treatment (100 nM, 72 h) significantly increased mitochondrial length and branching without changing the number of mitochondria per cell. In addition, this treatment caused a twofold increase in lipid peroxidation as determined with C11-BODIPY(581/591). Finally, digital imaging microscopy of cells loaded with hydroethidine, which is oxidized by O(2)(-)* to yield fluorescent ethidium, revealed that chronic rotenone treatment caused a twofold increase in the rate of O(2)(-)* production. MitoQ (10 nM, 72 h) did not interfere with rotenone-induced ethidium formation but abolished rotenone-induced outgrowth and lipid peroxidation. These findings show that increased mitochondrial O(2)(-)* production as a consequence of, for instance, complex I inhibition leads to mitochondrial outgrowth and that MitoQ acts downstream of this O(2)(-)* to prevent alterations in mitochondrial morphology.

Citing Articles

Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.

Montanari M, Mercuri N, Martella G Int J Mol Sci. 2025; 26(1.

PMID: 39795979 PMC: 11719863. DOI: 10.3390/ijms26010122.


Mitochondrial Morphofunctional Profiling in Primary Human Skin Fibroblasts Using TMRM and Mitotracker Green Co-staining.

Bergmans J, van de Westerlo E, Grefte S, Adjobo-Hermans M, Koopman W Methods Mol Biol. 2024; 2878():223-232.

PMID: 39546265 DOI: 10.1007/978-1-0716-4264-1_12.


Metabolic regulation of mitochondrial morphologies in pancreatic beta cells: coupling of bioenergetics and mitochondrial dynamics.

Tseng W, Chu C, Lee Y, Zhao S, Chang C, Ho Y Commun Biol. 2024; 7(1):1267.

PMID: 39369076 PMC: 11455970. DOI: 10.1038/s42003-024-06955-3.


Mitochondrial inorganic polyphosphate is required to maintain proteostasis within the organelle.

Da Costa R, Urquiza P, Perez M, Du Y, Khong M, Zheng H Front Cell Dev Biol. 2024; 12:1423208.

PMID: 39050895 PMC: 11266304. DOI: 10.3389/fcell.2024.1423208.


SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of vidarabine against rotenone-induced neural cell injury.

Li L, Zhang Y, Chen Z, Yao R, Xu Z, Xu C Heliyon. 2023; 9(11):e21695.

PMID: 38027872 PMC: 10643267. DOI: 10.1016/j.heliyon.2023.e21695.